← Leaderboards
Christina Gavegnano
Veterans Health Administration
$2,074,187
Attributed
$6,222,560
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2022–25$2.5M$1.9M$1.3M$625K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$6,222,560 · 3
VA$0 · 2
By mechanism
R01$6,222,560 · 3
I01$0 · 2
Top collaborators
- Cecile Delille Lahiri4 shared
- Susan Pereira Ribeiro4 shared
- William R Tyor4 shared
- Vincent Charles Marconi3 shared
- Albert Anderson1 shared
- Jennifer C Felger1 shared
- Andrew H Miller1 shared
Most similar at Veterans Health Administration
Same institution · by research overlap
- William R Tyor$6,673,682
- Vincent Charles Marconi$11,562,796
Others in their field
Other Rising Stars on “Cells”
- Mari Ostendorf · University Of Washington$51,931,230
- Sabrina Paganoni · Massachusetts General Hospital$30,122,905
- Suma Babu · Massachusetts General Hospital$30,122,905
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Jinsy Andrews · Columbia University Health Sciences$21,294,649
- Michelle Rives · Baylor College Of Medicine$20,650,593
Research focus
CellsPersonsAntiretroviral TherapySiteImmune ActivationLinkCytokineHiv InfectionsInflammatoryMortalityMagnetic Resonance ImagingMorbidity - Disease RateVirusSafetyInfectionFunctional DisorderInflammationFda ApprovedImmunologic MarkersComorbidityMouse ModelInflammatory MarkerJanus KinaseChronic
Grant awards (12)
Elucidating the role of the gut reservoir and inflammation in driving cardiovascular disease among persons living with HIV$745,702
R01 · FY2025 · HL
JAK Signaling as a Mechanism of Inflammation-related Reward and Motor Circuit Deficits in Depression$704,271
R01 · FY2025 · MH
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system$638,381
R01 · FY2025 · MH · contact PI
Validating a Humanized Mouse HIV Model for Cognitive Deficits and Novel Treatments$0
I01 · FY2025 · VA · contact PI
Leveraging Jak 1/2 Inhibition with Baricitinib Towards HIV Cure in the Veteran Population$0
I01 · FY2025 · VA · contact PI
Elucidating the role of the gut reservoir and inflammation in driving cardiovascular disease among persons living with HIV$730,789
R01 · FY2024 · HL
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system$638,381
R01 · FY2024 · MH · contact PI
Leveraging Jak 1/2 Inhibition with Baricitinib Towards HIV Cure in the Veteran Population$0
I01 · FY2024 · VA · contact PI
Elucidating the role of the gut reservoir and inflammation in driving cardiovascular disease among persons living with HIV$745,702
R01 · FY2023 · HL
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system$638,381
R01 · FY2023 · MH · contact PI
Elucidating the role of the gut reservoir and inflammation in driving cardiovascular disease among persons living with HIV$742,572
R01 · FY2022 · HL
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system$638,381
R01 · FY2022 · MH